The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

US Patent Granted for the Treatment of Cancer and Neurodegenerative Indications

22-May-2011 | Source : | Visits : 7973

NEW YORK, NY - NexGenix Pharmaceuticals Inc., a privately-held company developing treatments for cancer, neurodegenerative diseases, and orphan neurogenetic disorders, announced in a press release that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent for a platform of Hsp90 inhibitors based on derivatives of the naturally occurring pochonin family, Pochonia chlamydospora.

The platform of fully synthetic small molecules covered by this composition of matter patent was developed in the laboratory of Dr. Nicolas Winssinger at the University of Strasbourg (UNISTRA) and is exclusively licensed to NexGenix.

The patent, entitled "Macrocyclic Compounds Useful as Inhibitors of Kinases and Hsp90", provides an exclusivity period until August 2027. The patent specifically covers the proprietary scaffold and its composition along with a large library of compounds, including NexGenix's lead Hsp90 inhibitors aimed at cancer and neurodegenerative indications. The pochonin scaffold represents an advancement in Hsp90 inhibition beyond several molecules developed over the last decade based on radicicol and geldanamycin derivative (17-AAG) which have been shown to exhibit highly potent anti-tumor activity in numerous pre-clinical and clinical studies.

Professor Nicolas Winssinger of UNISTRA stated, "through a research collaboration agreement with NexGenix in 2007, we have developed a library of hundreds of molecules based on the scaffold that is covered by the patent allowed by USPTO. These molecules have been developed through an iterative process based on extensive in vitro and in vivo studies conducted by NexGenix in the selection of a lead candidate. I am looking forward to continuing these collaborative development activities."

X-ray crystallography studies have demonstrated deeper binding of NexGenix's molecules to the Hsp90 ATP binding pocket compared to other small-molecule Hsp90 inhibitor compounds for which crystallography has been published. This generally translates to interaction deep in the protein-binding pocket with the molecule remaining longer and thus inhibiting the protein for longer periods. Another major key differentiating point of the platform is that a subset of the library of over 500 molecules developed to date has the ability to cross the blood-brain barrier and the blood spinal cord barrier, making them particularly attractive candidate therapeutics for CNS indications, such as primary and secondary tumors of the CNS and neurodegenerative disorders.

Dr. Allan Rubenstein, NexGenix's CEO, said, "The grant of this US patent is part of a broad platform of intellectual property rights. NexGenix now has seven patent families allowed or pending covering the Company's compounds, various uses of these compounds, and other proprietary know-how. We believe that this matrix of intellectual property provides NexGenix with a unique position to benefit from the therapeutic applications of Hsp90 inhibitors."

The Company is currently in late stage pre-clinical development for its lead Hsp90 inhibitor with its unique ability to cross the blood-brain-barrier as a treatment for primary and metastatic brain tumors. NexGenix plans to seek regulatory approval to conduct a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of its lead Hsp90 inhibitor in advanced solid tumor malignancies.


Related Articles